|
US7393529B2
(en)
|
1998-04-09 |
2008-07-01 |
Idexx Laboratories, Inc. |
Methods and compositions for inhibiting binding of IgE to a high affinity receptor
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
GB0022101D0
(en)
*
|
2000-09-08 |
2000-10-25 |
Phogen Ltd |
Delivery of substances to cells
|
|
AU2210402A
(en)
|
2000-11-29 |
2002-06-11 |
Norwegian Radium Hospital Res |
Photochemical internalization for virus-mediated molecule delivery into the cyosol
|
|
EP1346059B1
(de)
|
2000-11-29 |
2012-05-23 |
PCI Biotech AS |
Photochemische internalisierung zur zuführung von molekülen in das zytosol
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US7517864B2
(en)
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
EP1432724A4
(de)
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
ATE495189T1
(de)
|
2003-08-15 |
2011-01-15 |
Univ Florida |
Die identifikation von polynukleotiden von porphyromonas gingivalis-virulenz zur diagnose, behandlung und beobachtung von periodontalerkrankungen
|
|
GB0321311D0
(en)
*
|
2003-09-12 |
2003-10-15 |
Phogen Ltd |
Delivery of substances to cells
|
|
JP4682152B2
(ja)
|
2003-12-31 |
2011-05-11 |
ザ・ペン・ステート・リサーチ・ファンデーション |
卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
|
|
JP2007526253A
(ja)
*
|
2004-02-19 |
2007-09-13 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
免疫刺激性ウイルスrnaオリゴヌクレオチド
|
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
|
US20060040882A1
(en)
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
ATE501252T1
(de)
|
2004-06-22 |
2011-03-15 |
Univ Illinois |
Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
|
|
WO2007002718A2
(en)
|
2005-06-27 |
2007-01-04 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of hif-1 and theraputic uses thereof
|
|
US20070213292A1
(en)
|
2005-08-10 |
2007-09-13 |
The Rockefeller University |
Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
|
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
|
JP5554925B2
(ja)
|
2006-01-20 |
2014-07-23 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
ヒト非小細胞肺癌における転座及び変異体rosキナーゼ
|
|
WO2007109097A2
(en)
|
2006-03-16 |
2007-09-27 |
Alnylam Pharmaceuticals, Inc. |
RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
|
|
JP5704741B2
(ja)
|
2006-03-31 |
2015-04-22 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Eg5遺伝子発現の抑制のための組成物および方法
|
|
PL2450437T3
(pl)
|
2006-04-14 |
2017-12-29 |
Cell Signaling Technology Inc |
Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
|
|
US8377448B2
(en)
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
|
BRPI0714875A2
(pt)
|
2006-07-21 |
2013-05-28 |
Silence Therapeutics Ag |
meios para inibir a expressço da proteÍna cinase 3
|
|
JPWO2008015841A1
(ja)
*
|
2006-08-02 |
2009-12-17 |
梅澤 喜夫 |
キナーゼ阻害性融合タンパク質と医薬組成物
|
|
WO2008030986A2
(en)
|
2006-09-06 |
2008-03-13 |
The Regents Of The University Of California |
Molecular diagnosis and classification of malignant melanoma
|
|
CA2678404C
(en)
|
2007-02-28 |
2019-03-19 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyury polypeptides and methods for use
|
|
EP3434259A1
(de)
|
2007-05-04 |
2019-01-30 |
Marina Biotech, Inc. |
Aminosäurelipide und verwendungen davon
|
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
|
AU2008286361B2
(en)
|
2007-08-13 |
2013-09-26 |
Takeda Pharmaceutical Company Limited |
IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
|
|
EP3072963B1
(de)
|
2007-10-18 |
2020-04-01 |
Cell Signaling Technology, Inc. |
Translokation und mutations-ros-kinase bei menschlichem nicht-kleinzelligem bronchialkarzinom
|
|
CA2703165A1
(en)
|
2007-10-22 |
2009-04-30 |
The Regents Of The University Of California |
Biomarkers for prenatal diagnosis of congenital cytomegalovirus
|
|
ES2489840T3
(es)
|
2008-03-05 |
2014-09-02 |
The Regents Of The University Of California |
Pronóstico molecular y clasificación de melanoma maligno en base a marcadores seleccionados entre la lista que consiste en RGS1, NCOA3, SPP1, PHIP
|
|
US10485879B2
(en)
|
2008-04-15 |
2019-11-26 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
|
|
US8703921B2
(en)
|
2008-04-15 |
2014-04-22 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for delivering inhibitory oligonucleotides
|
|
AU2009246134B2
(en)
|
2008-05-16 |
2016-03-03 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
|
|
US20110212021A1
(en)
|
2008-05-30 |
2011-09-01 |
Slack Frank J |
Targeted oligonucleotide compositions for modifying gene expression
|
|
CA2726052A1
(en)
|
2008-06-04 |
2009-12-10 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
|
EP2165710A1
(de)
|
2008-09-19 |
2010-03-24 |
Institut Curie |
Tyrosinkinaserezeptor Tyro3 als therapeutisches Target bei der Behandlung eines Blasentumors
|
|
CN104382853A
(zh)
|
2008-10-16 |
2015-03-04 |
玛瑞纳生物技术有限公司 |
基因沉默治疗剂的脂质体有效递送方法和组合物
|
|
NZ592905A
(en)
|
2008-10-27 |
2012-11-30 |
Baxter Int |
Models of thrombotic thrombocytopenic purpura and methods of use thereof
|
|
EP2198879A1
(de)
|
2008-12-11 |
2010-06-23 |
Institut Curie |
CD74-modulierender Wirkstoff zur Regulierung der Dendritenzellmigration und Verfahren zur Untersuchung der Bewegungsfähigkeit einer Zelle
|
|
SI2881402T1
(sl)
|
2009-02-12 |
2017-12-29 |
Cell Signaling Technology, Inc. |
Ekspresija mutantnega ros pri humanem raku jeter
|
|
WO2010091878A2
(en)
|
2009-02-13 |
2010-08-19 |
Silence Therapeutics Ag |
Means for inhibiting the expression of opa1
|
|
WO2010094491A1
(en)
|
2009-02-18 |
2010-08-26 |
Silence Therapeutics Ag |
Means for inhibiting the expression of ang2
|
|
JP2012520683A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害
|
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
|
AU2010226604A1
(en)
|
2009-03-19 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
|
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
|
EP2411517A2
(de)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
Rna-interferenz-vermittelte hemmung der genexpression von icam-1 (intercellular adhesion molecule 1) unter verwendung von sina (short interfering nucleic acid)
|
|
US20120010272A1
(en)
|
2009-03-27 |
2012-01-12 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
WO2010111490A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
CA2758189C
(en)
|
2009-04-10 |
2020-12-29 |
Association Institut De Myologie |
Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
|
|
WO2010124231A2
(en)
|
2009-04-24 |
2010-10-28 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
|
|
EP2266550A1
(de)
|
2009-06-15 |
2010-12-29 |
Institut Curie |
Antagonisten von ß-Catenin zur Prävention und/oder Behandlung neurodegenerativer Erkrankungen
|
|
CA2781896C
(en)
|
2009-12-09 |
2021-03-30 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
|
WO2011088435A1
(en)
|
2010-01-15 |
2011-07-21 |
Cornell University |
Methods for reducing protein levels in a cell
|
|
WO2011094759A2
(en)
|
2010-02-01 |
2011-08-04 |
The Regents Of The University Of California |
Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
|
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
|
WO2011139842A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
|
|
JP6033218B2
(ja)
|
2010-05-21 |
2016-11-30 |
ペプティメド, インコーポレイテッド |
がんを治療するための試薬および方法
|
|
WO2011151321A1
(en)
|
2010-05-31 |
2011-12-08 |
Institut Curie |
Asf1b as a prognosis marker and therapeutic target in human cancer
|
|
AU2011270896B9
(en)
|
2010-06-24 |
2015-05-07 |
Quark Pharmaceuticals, Inc. |
Double stranded RNA compounds to RhoA and use thereof
|
|
CN103068980B
(zh)
|
2010-08-02 |
2017-04-05 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
|
|
CN103328500B
(zh)
|
2010-08-04 |
2018-01-26 |
西兹尔生物技术有限公司 |
用于癌症的诊断和治疗的方法和化合物
|
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
|
RU2745848C2
(ru)
|
2010-08-17 |
2021-04-01 |
Сирна Терапьютикс, Инк. |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
|
JP6106085B2
(ja)
|
2010-08-24 |
2017-03-29 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
内部非核酸スペーサーを含む一本鎖RNAi剤
|
|
WO2012027467A1
(en)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
AU2011312504B2
(en)
|
2010-09-27 |
2016-12-22 |
The Children's Hospital Of Philadelphia |
Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
|
|
AU2011308567B2
(en)
|
2010-10-01 |
2015-09-03 |
Fundacion Centro Nacional De Investigaciones Oncologicas, Carlos Iii |
Manipulation of stem cell function by p53 isoforms
|
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
SG10201508981YA
(en)
|
2010-11-01 |
2015-11-27 |
Peptimed Inc |
Compositions Of A Peptide-Based System For Cell-Specific Targeting
|
|
EP2455456A1
(de)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Verwendung von Kinesininhibitoren bei der Behandlung von HIV-Infektion und Verfahren zu deren Abtastung
|
|
AU2012217723A1
(en)
|
2011-02-15 |
2013-08-29 |
Immune Design Corp. |
Methods for enhancing immunogen specific immune responses by vectored vaccines
|
|
EP2681314B1
(de)
|
2011-03-03 |
2017-11-01 |
Quark Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von lungenerkrankungen und läsionen
|
|
NZ616304A
(en)
|
2011-04-08 |
2016-01-29 |
Immune Design Corp |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
WO2012175481A1
(en)
|
2011-06-20 |
2012-12-27 |
Institut Curie |
Compositions and methods for treating leukemia
|
|
EP2557089A2
(de)
|
2011-07-15 |
2013-02-13 |
Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Zusammensetzungen und Verfahren zur Immunmodulation
|
|
DK2581448T3
(en)
|
2011-10-13 |
2015-04-27 |
Ass Inst De Myologie |
Tricyclo-DNA phosphorothioate
|
|
WO2013071154A1
(en)
|
2011-11-11 |
2013-05-16 |
Fred Hutchinson Cancer Research Center |
Cyclin a1-targeted t-cell immunotherapy for cancer
|
|
EP2802657B1
(de)
|
2012-01-12 |
2018-05-02 |
Quark Pharmaceuticals, Inc. |
Kombinationstherapie zur behandlung von gehör-und gleichgewichtsstörungen
|
|
EP2617434A1
(de)
|
2012-01-20 |
2013-07-24 |
Laboratorios Del. Dr. Esteve, S.A. |
HIV-1-Integrase-defiziente Immunogene und Verfahren zum Beladen von dentritischen Zellen mit besagten Immunogenen
|
|
WO2013123996A1
(en)
|
2012-02-24 |
2013-08-29 |
Astrazeneca Uk Limited |
Novel sirna inhibitors of human icam-1
|
|
WO2013158859A1
(en)
|
2012-04-18 |
2013-10-24 |
Cell Signaling Technology, Inc. |
Egfr and ros1 in cancer
|
|
WO2014043289A2
(en)
|
2012-09-12 |
2014-03-20 |
Quark Pharmaceuticals, Inc. |
Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof
|
|
EP2895608B1
(de)
|
2012-09-12 |
2018-12-05 |
Quark Pharmaceuticals, Inc. |
Doppelsträngige oligonukleotidmoleküle an p53 und verfahren zur verwendung davon
|
|
HK1214301A1
(zh)
|
2013-02-28 |
2016-07-22 |
箭头研究公司 |
治療epas1相關疾病的有機組合物
|
|
WO2014135655A1
(en)
|
2013-03-06 |
2014-09-12 |
Institut Curie |
Compositions and methods for treating muscle-invasive bladder cancer
|
|
UY35368A
(es)
|
2013-03-08 |
2014-10-31 |
Irm Llc |
Péptidos y composiciones para el tratamiento de daño articular
|
|
WO2014154898A1
(en)
|
2013-03-29 |
2014-10-02 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Prognosis and treatment of cancers
|
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
|
EP2853595A1
(de)
|
2013-09-30 |
2015-04-01 |
Soluventis GmbH |
NOTCH 1-spezifische siRNA-Moleküle
|
|
EA035259B1
(ru)
|
2014-02-14 |
2020-05-21 |
Иммьюн Дизайн Корп. |
Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
|
|
HRP20241236T1
(hr)
|
2014-05-13 |
2024-12-06 |
Novartis Ag |
Spojevi i pripravci za induciranje hondrogeneze
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
|
MX2017000630A
(es)
|
2014-07-15 |
2017-04-27 |
Immune Design Corp |
Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
|
|
SG10201806064XA
(en)
|
2014-08-27 |
2018-08-30 |
Peptimed Inc |
Anti-tumor compositions and methods
|
|
WO2016083624A1
(en)
|
2014-11-28 |
2016-06-02 |
Silence Therapeutics Gmbh |
Means for inhibiting the expression of edn1
|
|
MX2017011422A
(es)
|
2015-03-17 |
2017-11-10 |
Arrowhead Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen del factor xii.
|
|
TWI761305B
(zh)
|
2015-05-29 |
2022-04-21 |
美商愛羅海德製藥公司 |
抑制Hif2α基因表現之組合物及方法
|
|
WO2016196366A1
(en)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension of replicative lifespan in diseases of premature aging using p53 isoforms
|
|
CN115957337A
(zh)
|
2015-08-07 |
2023-04-14 |
箭头药业股份有限公司 |
乙型肝炎病毒感染的RNAi疗法
|
|
JOP20160211B1
(ar)
|
2015-10-01 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
EP3156497A1
(de)
|
2015-10-16 |
2017-04-19 |
Centre National de la Recherche Scientifique (C.N.R.S.) |
Trpv2 als biomarker und als therapeutisches target für melanome
|
|
EP3445385A4
(de)
|
2016-04-18 |
2019-11-20 |
The Trustees of Columbia University in the City of New York |
An der progression nichtalkoholischer steatohepatitis (nash) beteiligte therapeutische ziele
|
|
TWI912633B
(zh)
|
2016-06-06 |
2026-01-21 |
美商愛羅海德製藥公司 |
5'-環-磷酸修飾之核苷酸
|
|
EP3269734A1
(de)
|
2016-07-15 |
2018-01-17 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Verfahren und zusammensetzungen zur behandlung von krebs
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
US10450565B2
(en)
|
2017-01-10 |
2019-10-22 |
Arrowhead Pharmaceuticals, Inc. |
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
|
|
CN110234326B
(zh)
|
2017-01-30 |
2024-11-12 |
箭头药业股份有限公司 |
用于抑制因子xii基因表达的组合物和方法
|
|
TN2019000308A1
(en)
|
2017-07-06 |
2021-05-07 |
Arrowhead Pharmaceuticals Inc |
RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
|
|
EP3449978A1
(de)
|
2017-09-01 |
2019-03-06 |
Universite Paris Descartes |
Inhibitoren des arylkohlenwasserstoffrezeptors zur behandlung von weichteilsarkom und prävention von neurofibromwachstum und/oder transformation auf malignen peripheren nervenscheidentumoren
|
|
SG11201912178VA
(en)
|
2017-09-11 |
2020-01-30 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
|
MX2020001912A
(es)
|
2017-09-14 |
2020-03-24 |
Arrowhead Pharmaceuticals Inc |
Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
|
|
WO2019068326A1
(en)
|
2017-10-05 |
2019-04-11 |
Université D'aix-Marseille |
INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
|
|
CN111212909A
(zh)
|
2017-10-17 |
2020-05-29 |
箭头药业股份有限公司 |
用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
|
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
|
US12534728B2
(en)
|
2018-09-19 |
2026-01-27 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use
|
|
KR20210113273A
(ko)
|
2019-01-09 |
2021-09-15 |
애로우헤드 파마슈티컬스 인코포레이티드 |
HIF-2 알파 (EPAS1)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
|
|
TWI872048B
(zh)
|
2019-02-07 |
2025-02-11 |
美商艾羅海德製藥公司 |
用於B型肝炎病毒感染之RNAi劑
|
|
CA3133155A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron |
Combination therapy for the treatment for cancer
|
|
TW202103698A
(zh)
|
2019-04-18 |
2021-02-01 |
美商健生醫藥公司 |
用於治療b型肝炎病毒感染之組合療法
|
|
US20200332297A1
(en)
|
2019-04-18 |
2020-10-22 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
AU2020286462B2
(en)
|
2019-06-06 |
2026-07-02 |
Arrowhead Pharmaceuticals, Inc. |
Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)
|
|
WO2020255008A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
|
JP2022536945A
(ja)
|
2019-06-18 |
2022-08-22 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
B型肝炎ウイルス(HBV)ワクチンおよびHBVを標的化するRNAiの組合せ
|
|
EP3808763A1
(de)
|
2019-10-17 |
2021-04-21 |
Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Verbindungen zur immunmodulation
|
|
TW202130809A
(zh)
|
2019-10-29 |
2021-08-16 |
美商愛羅海德製藥公司 |
用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
|
|
WO2021175966A1
(en)
|
2020-03-04 |
2021-09-10 |
Ninovax |
Products for suppressing or reducing the expression or activity of a snorna and uses thereof in the treatment of cancer
|
|
WO2021178612A1
(en)
|
2020-03-05 |
2021-09-10 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
KR20220158011A
(ko)
|
2020-03-26 |
2022-11-29 |
애로우헤드 파마슈티컬스 인코포레이티드 |
PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법
|
|
EP4168547A1
(de)
|
2020-06-22 |
2023-04-26 |
Janssen Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von hepatitis-d-virusinfektionen
|
|
WO2022056273A1
(en)
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Lipid conjugates for the delivery of therapeutic agents
|
|
MX2023002939A
(es)
|
2020-09-11 |
2023-04-11 |
Arrowhead Pharmaceuticals Inc |
Plataformas para el transporte de farmacos hacia el musculo esqueletico y metodos de uso.
|
|
AU2021342155A1
(en)
|
2020-09-11 |
2023-04-13 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
|
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|
|
WO2022152869A1
(en)
|
2021-01-15 |
2022-07-21 |
Janssen Sciences Ireland Unlimited Company |
Use of oligonucleotides for individuals with hepatic impairment
|
|
WO2022216920A1
(en)
|
2021-04-08 |
2022-10-13 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
|
|
BR112023024615A2
(pt)
|
2021-05-28 |
2024-02-20 |
Arrowhead Pharmaceuticals Inc |
Agentes de rnai para inibir expressão de mucina 5ac (muc5ac), composições dos mesmos, e métodos de uso
|
|
US11629349B2
(en)
|
2021-06-21 |
2023-04-18 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
|
CN117616121A
(zh)
|
2021-07-09 |
2024-02-27 |
葛兰素史密斯克莱知识产权(第3号)有限公司 |
寡核苷酸用于具有肾脏损伤的个体的用途
|
|
US20230241118A1
(en)
|
2021-10-20 |
2023-08-03 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
JP2025522433A
(ja)
|
2022-06-15 |
2025-07-15 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
スーパーオキシドジスムターゼ1(SOD1)の発現を阻害するためのRNAi剤、その組成物、及び使用の方法
|
|
WO2024089013A1
(en)
|
2022-10-25 |
2024-05-02 |
Peptomyc, S.L. |
Combination therapy for the treatment of cancer
|
|
EP4634382A1
(de)
|
2022-12-16 |
2025-10-22 |
Université de Strasbourg |
Gegen claudin-1 gerichtete rnai-basierte therapien zur behandlung und prävention von fibrotischen erkrankungen
|
|
EP4658294A2
(de)
|
2023-02-02 |
2025-12-10 |
University of Rochester |
Kompetitiver ersatz von gliazellen
|
|
EP4410825A1
(de)
|
2023-02-03 |
2024-08-07 |
Servizo Galego de Saude |
Fragmente der n-terminalen domäne von gsdmb zur behandlung von krebs
|
|
EP4684015A2
(de)
|
2023-03-21 |
2026-01-28 |
Arrowhead Pharmaceuticals, Inc. |
Rnai-mittel zur hemmung der expression des komplementfaktors b (cfb), pharmazeutische zusammensetzungen daraus und verfahren zur verwendung
|
|
EP4724100A1
(de)
|
2023-06-07 |
2026-04-15 |
Fundació Privada Institut d'Investigació Oncològica de Vall Hebron |
Kombinationstherapie mit mek-hemmern zur behandlung von krebs
|
|
IL325025A
(en)
|
2023-06-07 |
2026-01-01 |
Fundaci? Privada Inst Dinvestigaci? Oncol?Gica De Vall Hebron |
Combination therapy with BRAF inhibitors for cancer treatment
|
|
EP4473974A1
(de)
|
2023-06-07 |
2024-12-11 |
Peptomyc, S.L. |
Omomyc und kras-hemmern kombinationstherapie zur behandlung von krebs
|
|
AU2024331015A1
(en)
|
2023-08-30 |
2026-02-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use
|
|
WO2025072748A2
(en)
|
2023-09-29 |
2025-04-03 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
IL330211A
(en)
|
2023-12-20 |
2026-08-01 |
Arrowhead Pharmaceuticals Inc |
RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), their compositions and methods of use
|
|
WO2025172510A1
(en)
|
2024-02-15 |
2025-08-21 |
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Compounds for treating diseases
|
|
EP4616864A1
(de)
|
2024-03-11 |
2025-09-17 |
Peptomyc, S.L. |
Verbindung zur behandlung von autoimmunerkrankungen
|
|
WO2025196505A2
(en)
|
2024-03-22 |
2025-09-25 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
|
|
WO2025212467A1
(en)
|
2024-03-31 |
2025-10-09 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use
|
|
US20250333742A1
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|
|
WO2025242321A1
(en)
|
2024-05-24 |
2025-11-27 |
Glaxosmithkline Intellectual Property (No.3) Limited |
Novel use
|
|
WO2025265013A2
(en)
|
2024-06-20 |
2025-12-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use
|
|
WO2026044017A2
(en)
|
2024-08-21 |
2026-02-26 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|